Impact of temporomandibular disorder comorbidity on pain, quality of life, sleep, and functional outcomes in chronic migraine patients not using preventive treatment: a cross-sectional study.
{"title":"Impact of temporomandibular disorder comorbidity on pain, quality of life, sleep, and functional outcomes in chronic migraine patients not using preventive treatment: a cross-sectional study.","authors":"Alper Mengi, Ugur Uygunoglu","doi":"10.1080/01616412.2025.2507755","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate pain, quality of life, sleep, and functional outcomes between chronic migraine (CM) patients with temporomandibular disorder (TMD) and patients with CM alone.</p><p><strong>Methods: </strong>Thirty one patients with CM and thirty one patients with CM+TMD were recruited in the study. All patients had not been on preventive treatment for CM or TMD in the previous three months. TMD was examined by physical examination, guided by the subdomains of the Helkimo Clinical Dysfunction Index (HCDI). All patients were evaluated for allodynia using the Allodynia Symptom Checklist (ASC-12), quality of life using the 36-item Short Form Health Survey (SF-36), headache-related disability using the Migraine Disability Assessment Scale (MIDAS) and the Headache Impact Test (HIT-6), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).</p><p><strong>Results: </strong>The average pain intensity was higher in patients with CM+TMD (<i>p</i> < 0.001). The number of patients with a migraine attack duration of more than 3 days were significantly higher in the same group (<i>p</i> = 0.001). ASC-12 scores were significantly elevated in patients with CM+TMD (<i>p</i> < 0.001). MIDAS and HIT-6 scores were significantly higher in the CM+TMD patient group (<i>p</i> = 0.010, <i>p</i> < 0.001, respectively). HCDI score was significantly positively correlated with age, BMI, average number of headache days in a month, ASC-12 score, PSQI sleep disturbance domain score, and PSQI total score (<i>r</i> = 0.625, 0.406, 0.417, 0.484, 0.499, and 0.487, respectively).</p><p><strong>Conclusion: </strong>In patients with CM, TMD comorbidity significantly associated with high average pain intensity, migraine attack duration, and allodynia. Physicians managing headaches should not overlook TMD symptoms in CM and should benefit from collaborating with TMD specialists to address TMD symptoms effectively.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01616412.2025.2507755","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To investigate pain, quality of life, sleep, and functional outcomes between chronic migraine (CM) patients with temporomandibular disorder (TMD) and patients with CM alone.
Methods: Thirty one patients with CM and thirty one patients with CM+TMD were recruited in the study. All patients had not been on preventive treatment for CM or TMD in the previous three months. TMD was examined by physical examination, guided by the subdomains of the Helkimo Clinical Dysfunction Index (HCDI). All patients were evaluated for allodynia using the Allodynia Symptom Checklist (ASC-12), quality of life using the 36-item Short Form Health Survey (SF-36), headache-related disability using the Migraine Disability Assessment Scale (MIDAS) and the Headache Impact Test (HIT-6), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).
Results: The average pain intensity was higher in patients with CM+TMD (p < 0.001). The number of patients with a migraine attack duration of more than 3 days were significantly higher in the same group (p = 0.001). ASC-12 scores were significantly elevated in patients with CM+TMD (p < 0.001). MIDAS and HIT-6 scores were significantly higher in the CM+TMD patient group (p = 0.010, p < 0.001, respectively). HCDI score was significantly positively correlated with age, BMI, average number of headache days in a month, ASC-12 score, PSQI sleep disturbance domain score, and PSQI total score (r = 0.625, 0.406, 0.417, 0.484, 0.499, and 0.487, respectively).
Conclusion: In patients with CM, TMD comorbidity significantly associated with high average pain intensity, migraine attack duration, and allodynia. Physicians managing headaches should not overlook TMD symptoms in CM and should benefit from collaborating with TMD specialists to address TMD symptoms effectively.
目的:探讨慢性偏头痛(CM)合并颞下颌紊乱(TMD)和单纯CM患者的疼痛、生活质量、睡眠和功能结局。方法:选取31例CM患者和31例CM+TMD患者。所有患者在前三个月内均未接受CM或TMD预防性治疗。在Helkimo临床功能障碍指数(HCDI)子域指导下,通过体格检查检查TMD。使用异位性疼痛症状检查表(ASC-12)评估所有患者的异位性疼痛,使用36项简短健康调查(SF-36)评估生活质量,使用偏头痛残疾评估量表(MIDAS)和头痛影响测试(HIT-6)评估头痛相关残疾,使用匹兹堡睡眠质量指数(PSQI)评估睡眠质量。结果:CM+TMD患者的平均疼痛强度较高(p p = 0.001)。CM+TMD患者ASC-12评分显著升高(p = 0.010, p r = 0.625, 0.406, 0.417, 0.484, 0.499, 0.487)。结论:在CM患者中,TMD合并症与高平均疼痛强度、偏头痛发作持续时间和异常性疼痛显著相关。治疗头痛的医生不应忽视CM患者的TMD症状,并应与TMD专家合作,有效地解决TMD症状。
期刊介绍:
Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields.
The scope of the journal includes:
•Stem cell applications
•Molecular neuroscience
•Neuropharmacology
•Neuroradiology
•Neurochemistry
•Biomathematical models
•Endovascular neurosurgery
•Innovation in neurosurgery.